IACH 2021 | Updates on CAR T-cells in lymphoma
Anna Sureda, MD, PhD, of the Catalan Institute of Oncology, Barcelona, Spain, gives an update on the use of chimeric antigen receptor (CAR) T-cell therapy in lymphoma, and highlights key points from her presentation at IACH 2021. The development of CAR T-cell therapy has significantly impacted the treatment of patients with lymphoma, with multiple lines of evidence confirming the efficacy of this therapy. Dr Sureda comments on data investigating the role of CAR T-cells as a first- and second-line treatment for B-cell lymphoid malignancies, and discusses clinical trials demonstrating the efficacy and low toxicity of CD19 CAR T-cells in patients with relapsed/refractory follicular and mantle cell lymphoma. This interview took place at the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH), which took place virtually in 2021.
Transcript (edited for clarity)
Hi, everybody. My name is Anna Sureda. I work in Barcelona, Spain. And I gave a presentation on the role of CAR T-cells in patient with lymphoma. So, CAR T-cells have really modified the treatment landscape for patients with aggressive B-cell lymphoma that are refractory or that have relapsed after two or more lines of chemotherapy. These patients with the standard of care treatment had really an awful long-term outcome...
Hi, everybody. My name is Anna Sureda. I work in Barcelona, Spain. And I gave a presentation on the role of CAR T-cells in patient with lymphoma. So, CAR T-cells have really modified the treatment landscape for patients with aggressive B-cell lymphoma that are refractory or that have relapsed after two or more lines of chemotherapy. These patients with the standard of care treatment had really an awful long-term outcome. And nowadays, we have data coming from the three pivotal prospective clinical trials. We have data coming from real-world evidence, from both from US and Europe, indicating that we are able to cure a significant proportion of these patients. We are also able to start to identify which patients might be better candidates for CAR T-cells in terms of efficacy, and also in terms of safety and toxicity of the procedure.
And if we look a little bit into the future and if we still discuss aggressive B-cell lymphoma, basically diffuse large B-cell lymphoma and other less frequent histologies, CAR T-cells are being moved into early phases of the disease treatment. So, we will see pretty similar results of the Phase III prospective clinical trials that compare head-to-head autotransplant with CAR T-cells in second-line therapy. There are data looking at the role of CAR T-cells in first-line treatment. We have dual CAR T-cells. We will have more information in the future on allogeneic CAR T-cells.
And we will also have probably more definitive information on the role of CAR T-cells in other B-cell lymphoid malignancies. I presented some data on the two Phase II pivotal trials that look at the efficacy and toxicity of CD19 CAR T-cells in patient with follicular lymphoma, both axi-cel and tisagen, really with excellent complete remission rates, very interesting progression-free survival and duration of response, and a safety profile that seems a little bit better than what we are used to see in patient with aggressive B-cell lymphoma.
And of course, we also have data and I presented them in my presentation on the role of CAR T-cells, CD19 CAR T-cells, in patient with mantle cell lymphoma that have been refractory or that have relapsed to conventional treatment. Also really a very high complete remission rate and very interesting progression-free survival, duration of response, and overall survival curves.
So, as a summary, I think that we are basically witnessing a completely different area in the treatment of all these B-cell lymphoid malignancies and probably in the near future we will see additional advances that will also significantly impact in the outcome of these patients.
Read more...
